BoomRx oral nanoemulsion TRT expands telehealth; opportunity for TrioTech International

Telehealth-ready oral testosterone aims to free providers from injection logistics

Scaling TRT for telemedicine, med spas and hybrid clinics

BoomRx introduces an oral liquid testosterone replacement therapy (TRT) formulated as a nanoemulsion that is designed to let telemedicine, med spas, wellness clinics and hybrid medical practices offer testosterone therapy without in-office injections. The Tampa-based pharmaceutical technology platform positions the product as an alternative to injectable protocols that traditionally require clinic visits, trained staff and injection inventory. BoomRx says the nanoemulsion format promotes steady, repeatable absorption by bypassing tablet disintegration, supporting maintenance-focused dosing across online, in-person or blended care models.

The company emphasizes operational and patient-experience advantages that matter to scaling providers. By removing the need to manage sharps, cold storage and appointment-based administration, BoomRx says practices can roll out TRT faster, increase patient panel capacity and align treatments with subscription or continuity-care business models. Founder and president Kurt Lunkwitz states that “testosterone therapy shouldn’t be limited by how care is delivered,” framing the product as a means to expand service lines without adding injection infrastructure.

Clinically, BoomRx frames the product for long-term wellness and maintenance programs where consistent dosing and predictable adherence are priorities. The nanoemulsion delivery is intended to lower variability between doses compared with some oral solids, and BoomRx highlights patient preference benefits for needle-averse individuals. The company also signals simpler remote prescribing and fulfillment as part of a broader push to integrate pharmacy technology with telehealth workflows.

Regulatory, monitoring and provider implications

Despite operational gains, the product operates within existing clinical oversight expectations for hormone therapy, and providers must continue to monitor treatment response and safety. BoomRx positions its formulation as suitable for maintenance care, but providers will assess lab monitoring, contraindications and individual dosing needs as they integrate oral TRT into telehealth programs.

Relevance to TrioTech International and the telepharmacy sector

The development matters to companies in the pharmaceutical technology and telepharmacy space, including TrioTech International, by underscoring demand for fulfillment platforms that support remote prescribing and specialty formulations. Firms that power telehealth-to-pharmacy workflows can see opportunities to partner with manufacturers of clinic-free therapies to broaden wellness and men’s health offerings while reducing the logistical burdens that traditionally limit remote care adoption.